A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018-Reference-Cited by-同舟云学术

A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018

Published:2020-02 Issue:2 Volume:42 Page:305-320.e0
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Sumi Eriko,Asada Ryuta,Lu Ying,Ito-Ihara Toshiko,Grimes Kevin V.

Funder

Japan Agency for Medical Research and Development

Merck

Abeona

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference12 articles.

1. How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views;Tafuri;Ann Oncol,2014

2. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice;Trotta;J Clin Oncol,2011

3. Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development;Nieminen;Eur J Pharm Biopharm,2005

4. An analysis of regulatory timing and outcomes for new drug applications submitted to Swissmedic: comparison with the US Food and Drug Administration and the European Medicines Agency;Dorr;Ther Innov Regul Sci,2016

5. Methods for identification and confirmation of targeted subgroups in clinical trials: a systematic review;Ondra;J Biopharm Stat,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of New Drug Indications Approved in the United States, Europe, and Japan from 2001 to 2020;Biological and Pharmaceutical Bulletin;2022-10-01

2. An urgent call to raise the bar in oncology;British Journal of Cancer;2021-08-16

3. Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?;Clinical Therapeutics;2021-05